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Abstract 
 
This article aims to specify the arguments supporting the world’s two most 
widespread models for obtaining blood and plasma: the so called paid-donation model, 
by which blood and plasma are obtained in exchange for payment, and the altruistic 
model, by which blood and plasma
1
 are obtained through unpaid donations. The 
intention is to make an ethical evaluation. 
 
Blood management is a little known subject that needs to be divulged in the face of 
the legal and policy changes that are occurring worldwide with access to universal 
healthcare. Therefore, it is imperative to understand what use is made of this raw 
material, how countries organize themselves to obtain it, and to evaluate whether it is 
necessary to consider new lines of action, given that it is a limited resource. Blood can 
only be obtained from living persons, so how it is obtained opens a crucial ethical 
debate, bringing to the fore what conception we humans have of ourselves, what value 
we give health and what model of society we want. 
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Introduction 
 
Before directly addressing models for obtention, we will briefly define related terms 
–donation, solidarity and altruism– as they are often used erroneously. Rather than 
making a philosophical inquiry, the aim is to clarify the common use of these words.  
 
                                                             
1 From now when refers to blood, though no explicitly, is also valid for plasma. 
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According to the Spanish Royal Academy’s dictionary, donation is "1. Action and 
effect of donating. 2. Liberality in gratuitously giving something that belongs to them to 
another who accepts it”2 However, the term donation is often used improperly when, 
depending on the country or institution, it is remunerated. Someone from whom blood is 
drawn in exchange for payment, however small, is not making a donation but a sale. It 
is important to note this, as the use of the term 'donation' is reiterated in the context of 
obtention against payment. Furthermore, the term 'altruistic donation' is also used, 
which is redundant. In this article, care has been taken with the terminology, but 
sometimes the word 'donor' is also used when talking about a sale for lack of other 
terms and to avoid naming them 'sellers', although it is better suited. 
 
Solidarity is “1. Circumstantial commitment to the cause or the endeavor of others. 
2. Duty or liability “in solidum.”3 The philosopher Victoria Camps points out that 
solidarity is the condition of justice, the measure that compensates for the shortcomings 
of this fundamental virtue. Camps reveal the will to broaden the sense of self and to do 
so it should include the will of approximation among human beings: benevolence.4 
Altruism is "diligence in seeking the welfare of others even at the expense of oneself.”5 
Both concepts seek the well-being of others. The difference is that in the first case they 
do not have to sacrifice themselves to be supportive, while the altruists go one step 
further and make sacrifices for the good of others. Donation, altruism and solidarity are 
human predispositions in which the figure of otherness is very present. They are 
essential in all spheres of community life and make these more equitable and just. They 
are all taught and instilled. 
 
 
A bioethical issue 
 
This article falls within the scope of bioethics and takes principlism as its paradigm, 
being the most widely used in the field of health. It offers four principles to guide moral 
decisions in medical practice and biomedicine. They are the principles of beneficence, 
                                                             
2 Real Academia Española (RAE) 
3
 Ibid. 
4 Camps, V., Virtudes públicas, Madrid: Espasa Calpe, 1990, pp. 35 
5 Op. cit., RAE 
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non maleficence, autonomy and justice. They are prima facie principles: in case of 
conflict, the principle which is to prevail is to be assessed according to each case.
6  
 
Our starting point here is the specific case of the ethical aspects of blood collection; 
but we will gradually escalate and pose ethical problems concerning the configuration 
of the patent system, the institutions –both local and global– that legislate on global 
health issues, and the role of policies that support them. We are faced with a question of 
biopolitics: of how the powers that be –the political ones– manage our lives. In this 
regard, the importance of bioethics as a branch of applied ethics that reflects on life 
sciences and their moral implications is vindicated. 
 
Medicine and health are social products that require a profound sense of ethics and 
humanism. Curing diseases falls within the ethics of civic minimums, of justice, but 
also within the organization of a community: how to get limited resources (such as 
blood) and the responsibility of institutions, associations and public health policy. 
Biomedicine needs people –or their parts– for research, for clinical trials, and to 
manufacture drugs. Therefore, it is important to generate a debate about the various 
models for obtaining raw materials of human origin. 
 
 
What is the current issue? 
 
Blood and plasma 
 
First of all, it is important to understand what kind of resource we are talking about, 
why it is so necessary at a vital level, and what it means to become a donor. 
 
Blood is a fluid tissue essential to life and can cure very serious illnesses, but 
may also cause them. The blood tissue is used for transfusions, and its strictly liquid 
                                                             
6 According to Beauchamp and Childress, the principle of beneficence indicates "a moral obligation to act 
for the benefit of others", while the principle of non-maleficence refers to provoking no harm. The 
principle of autonomy is opposed to the long tradition of paternalism in the medical and clinical spheres, 
where the doctor takes all decisions without taking into account the specific preferences of each patient. It 
vindicates the patient's freedom to make their own decisions and the doctor becomes the professional who 
informs and advises. Finally, the principle of justice, which does not refer to the personal sphere but to 
that of the community, defends equal access to healthcare and also equitable distribution of medical 
resources. 
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phase –plasma– is used for research and the production of biological medicines. 
Therapeuticals obtained from plasma are often the only effective treatment for curing 
certain diseases.
7  
 
What is involved in obtaining blood and plasma?  
 
Giving blood takes between 20 and 30 minutes with a minimum interval of around 
two months.
8 
It involves minor discomfort and has no adverse physical effects. 
Extraction does not require extensive infrastructure: it can be carried out in mobile units 
and in hospitals without too much specific equipment. 
 
When donating plasma, some things change. Initially, there are two different types 
of collection depending on what and how it is obtained. One is termed Recovered 
Plasma. This takes about forty minutes and is for internal hospital use. It may only be 
extracted every three months, and no component is returned to the donor organism. The 
other type is Source Plasma, which takes 90 to 120 minutes to extract and is strictly 
intended for the industry. It is recommended extractions be made no more frequently 
than every 15 days, with a maximum of 12 times a year.
9
 
 
The need for blood and plasma in the world 
 
The West is self-sufficient in blood components (products obtained from whole 
blood) but not in blood products (pharmaceutical products, the active ingredient of 
which comes from plasma). The constant need for these involves finding a stable source 
of supply that can only come from living human beings. It is important to create a blood 
collection and management model, without forgetting that the aim should not be 
lucrative, but curative. 
 
Spain is self-sufficient in red blood cells for internal use in hospitals, but not in 
plasma, which is used in the industry. The data shows that many European countries 
that have implemented the altruistic model are not self-sufficient. In fact, 76% of the 
                                                             
7
 Grifols Department of Public Affairs. (2014). Bioethics of Compensated Plasma Donation, p. 1 
8 Cruz Roja Española, ¿Puedo donar si…?  http://www.donarsangre.org/puedo-donar-si/ 
9 Grifols pioneering spirit, La ética en la donación de plasma. pp. 4-8 
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plasma used in the manufacture of blood products worldwide is the so-called Source 
Plasma, of which 85% comes from the United States
10
, where remunerated extractions 
are possible: 
 
“With the adoption of World Health Assembly resolution WHA63.12 Availability, 
safety and quality of blood products (3) in 2010, working towards self-sufficiency in 
safe blood and blood products based on voluntary non-remunerated donation
11
 is a 
policy direction already agreed upon by World Health Organization (WHO) 
Member States. However, self-sufficiency is not yet a reality in many countries with 
inadequate supplies of blood and blood products from voluntary non-remunerated 
donors (VNRD), and dependence on family/replacement donation systems and 
payment to blood and plasma donors to fill the gaps between supply and demand. 
The increasing global demands for blood and blood products, the complex nature of 
systems to supply these products, the inability of many national health systems to 
meet these urgent needs and the impact of globalization have also resulted in a rapid 
expansion of international commercial activities in relation to the provision of blood 
and blood products, as shown by increasing global markets in commercial plasma 
collection.”12 
 
This situation opens the debate on whether countries that use the altruistic model 
should approach paying for donations in order to achieve self-sufficiency or if, on the 
contrary, paying for the obtention of human tissue is unethical and that morally creative 
solutions should be sought in order to achieve self-sufficiency. 
 
 
An altruistic or a remunerative model? 
 
The most widespread model in Europe is altruistic. This does allow for reimbursing 
the direct costs involved in the donation (transport and snack). It makes no difference 
between giving blood or plasma, nor if it requires more or less time for extraction, nor 
whether any of its components are returned. It considers that what is being given is a 
liquid tissue from a living human being. 
                                                             
10 Ibid., pp. 9-18 
11 Here is an example of the misuse of the word 'donor'. The concept used in this article, 'voluntary non-
remunerated donation' is redundant given that the meaning of the word 'donation' implies non-
remuneration, that it is a free and voluntary act. If instead there is compensation, one should speak of 
'sale'. Throughout the article one can see how the same mistake is made in several quotations. Donation is 
very commonly qualified by the adjective "voluntary" and those who are paid are also –incorrectly– 
called 'donors', which makes it difficult to distinguish the two types (of 'donor'). 
12
 World Health Organization (WHO). Towards Self-Sufficiency in Safe Blood and Blood Products based 
on Voluntary Non-Remunerated Donation: Global Status 2013, p. 3 
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Extraction and use do generate some costs: the "costs of processing blood." The 
National Health Services usually assumes the cost, except in private hospitals where 
health insurers or the patients themselves do so. 
 
In 2013, a meeting of WHO and other international health and human rights 
organizations was held in Europe to draft The Rome Declaration on Achieving Self-
Sufficiency in Safe Blood and Blood Products, based on Voluntary Non Remunerated 
Donation, which defends the altruistic model and requires countries to be self-sufficient 
and to manage their blood.
13
 
 
The paid model is used especially in the United States. It coexists with the 
altruistic model as they are not considered incompatible. The paid model differentiates 
between extraction types, and labels extractions according to whether the acquisition is 
voluntary or paid.
14
 If it is in exchange for remuneration, no distinction is made on the 
basis of who has paid for it.
15
 
 
Arguments for the altruistic model 
 
The reasons for the altruistic model are fundamentally clinical and of efficiency. 
Donations are considered safer because by not having any financial compensation, it 
prevents people who are interested in compensation, even though they know they are 
carriers of an infectious disease, from trying to pass the medical interview to obtain 
money. Therefore, the altruistic model guarantees safety for both the donor and the 
recipient. WHO stresses this when it says that "voluntary non-remunerated blood 
donation is the cornerstone of a safe and sufficient blood supply and is the first line of 
                                                             
13 High-level Policy Makers Forum on Achieving Self-sufficiency in Safe Blood and Blood Products, 
based on Voluntary Non-Remunerated Donation, The Rome Declaration on Achieving Self-Sufficiency in 
Safe Blood and Blood Products, based on Voluntary Non-Remunerated Donation, Rome, Italy 8-9 
October 2013, p. 1 
14 In general, all those extractions obtained voluntarily are those used for several types of transfusions, 
while the extractions that have been paid for are usually for the manufacture of medicines, research or 
clinical trials. 
15 U.S Food and Drug Administration. Protecting and Promoting Your Health. CPG Sec. 230.150 Blood 
Donor Classification Statement, Paid or Volunteer Donor. p.1 
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defense against the transmission of infectious diseases through transfusion.”16 
Similarly, this model favors the cost-effective use of this resource: fewer units are 
discarded upon passing quality controls. Furthermore, paying for the extraction of blood 
might also result in charging the patients who need it most. 
 
But there are also ethical arguments, such as social solidarity. The donors’ 
motivation is to help, to collaborate and, at least, to obtain psychological benefit in 
knowing that they form part of a community that will "return" the effort when they need 
it. It is an exchange and not a sale exploiting the human body, as the European Council 
stated in 1997 at the Oviedo Convention on Human Rights and Biomedicine:
17
 
 
“Recognizing that payment for the donation of blood, plasma and other blood 
components not only threatens safety but also contravenes the Council of Europe’s 
Oviedo Convention on Human Rights and Biomedicine of 1997, which explicitly 
prohibits any financial gain from the human body and its parts, which erodes 
community solidarity and social cohesion that can be enhanced by the act of 
voluntary non-remunerated donation.”18 
 
Advocates of altruism argue that providing a financial reward could be coercive 
toward those in need of money, thus increasing vulnerability and attacking social 
cohesion. As the Rome Declaration highlights: 
 
“(...) may exploit the poor and vulnerable by providing them with financial 
incentives to donate and that voluntary non-remunerated blood donor 
programmes may be compromised or undermined by the presence of parallel 
systems of paid donation.”19 
 
Other ethical arguments refer to the concept of human dignity: liberalizing sales 
implies trading with the human body, which we view as inalienable (without going as 
far as sacralizing the body; we are for the right to the possession of our bodies, but it is 
not considered ethical to trade in them); that is, it is argued that it is unethical to put a 
price on the human body or any of its parts, whether regenerable or not. 
                                                             
16 WHO Expert Group on Self-sufficiency in Safe Blood and Blood Products based on VNRBD, Expert 
Consensus Statement on achieving self-sufficiency in safe blood and blood products, based on voluntary 
non-remunerated blood donation (VNRBD), 2012, p. 3 
17 Instituto Borja de Bioética. Convenio sobre los Derechos Humanos y la Biomedicina. Bioética&Debat 
(año II, nº5). Barcelona. p. 5 
18
 Op. cit., High-level Policy Makers Forum on Achieving Self-sufficiency in Safe Blood and Blood 
Products, based on Voluntary Non-Remunerated Donation, p. 2 
19 Ibid. 
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Advocates of altruism believe that this should be the only model because the 
paid providers endanger their lives, and it may cause an imbalance in the National 
Health System. Promoting values such as solidarity, the feeling of belonging to a 
community or of mutual assistance, helps them propagate and spread. Breaking with 
this would be ethically and socially disastrous. 
 
The altruistic model advocates for a public health model where a resource such 
as blood is in the hands of public institutions and owned by all citizens. WHO believes 
that if there is to be social justice, an equitable health model is necessary, without being 
subjected to market forces: 
 
“Prevention of the commercialization of blood donation and exploitation of blood 
donors are important ethical principles on which a national blood system should be 
based. The right to equal opportunity in access to blood and blood products of 
uniform and high quality based on patients needs is rooted in social justice and the 
social right to health care.”20 
 
Criticism of the altruistic model 
 
Criticism of the altruistic model revolves around the argument for efficiency: it is a 
model that cannot guarantee national self-sufficiency. Those who oppose altruism 
believe that forbidding compensation may lead to a global catastrophe with undesirable 
consequences: 
 
“The introduction of legislation to prevent payment in cash for the donation of 
plasma will result in catastrophic undesired outcomes. The total number of 
donations that our members collect annually to manufacture the life-saving therapies 
approaches 30 million per year. There is no alternative for these donations.”21 
 
Therefore, they do not accept or support the reasons that lead to the defense of 
altruism as it is precisely compensation that meets the demand. This is demonstrated by 
data from European countries that are siding with this option: 
 
                                                             
20
 Op. cit., WHO Expert Group on Self-sufficiency in Safe Blood and Blood Products based on VNRBD, 
p. 5 
21 Bult, J.M., President and CEO from Plasma Protein Therapeutics Association to Dr. Kieny, MP 
Assistant Director General Health Systems and Innovation, World Health Organization, 2014 
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“Of the 29 European countries that supplied sufficient data for the European 
Committee on Blood Transfusion (ECBT) to perform a tern analysis, the two 
countries with highest statistically significant increases in litres of plasma for 
fractionation per capita between 2001 and 2008 were the Czech Republic and 
Germany, which allow compensated donation.”22 
 
Moreover, the clinical argument according to which all those who are aware that 
they are at risk of harboring an infectious disease  and may offer donation, endangering 
the health of recipients in the absence of the filter of self-exclusion is denied. This 
argument has become obsolete: currently protocols to be followed in both models 
ensure the quality of extractions. It is also argued that the economic incentive is not to 
the detriment of social and community values as remuneration precisely recognizes the 
efforts of the donor: 
 
“In the United States there is no policy restricting remunerated voluntary 
donations of plasma. (...) There is no evidence that remunerated plasma 
donations have increased safety risks for patients in the United States. Rather, 
there is a robust and safe supply of plasma products for the ever-increasing 
demand for such products to treat various rare and chronic disorders.”23 
 
Finally, in preparing conventions and declarations on this subject, the parties 
involved have never all been heard. In meetings between public institutions and 
organizations, the private agencies that regulate these therapies and other countries that 
buy the plasma have not been invited; not even the industry’s private sector. Giving 
these parties a hearing would be desirable as they can provide argumentation. The 
outcome of the discussion would doubtlessly be more valid and fair. 
 
In this sense, the American Plasma Users Coalition considers the Rome Declaration 
lacks a sense of reality: 
 
“This Rome Declaration lacks a sense of reality. It is incomprehensible that 
some WHO and government officials do not seem to realize the enormous 
negative impact that the implementation of some of the suggestions will have on 
the patients whose lives are dependent on the therapies that are being 
manufactured from plasma obtained from compensated donors by the private 
sector industry.”24 
                                                             
22 Op. cit., Grifols pioneering spirit, p. 13 
23
 American Plasma Users Coalition to Dr. Chan, M. Director General, World Health Organization, 
Geneva, Switzerland, 2014 
24 Ibid. 
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Arguments for a paid model  
 
The reasons given for a paid model are similar to those of the altruistic model. 
Firstly, the dual US model (where plasma collection is rewarded but blood donation is 
not) is strictly regulated and controlled by the Health Authorities –US Food and Drug 
Administration– and coexists with the altruistic model. This covers the needs of the 
country and allows export of both plasma and blood products.
25
 According to this 
clinical and efficiency-oriented argument, the fact that it reaches the necessary 
objectives legitimizes the model. 
 
Grifols, a multinational, is a leader in the production of biological medicines 
derived from plasma, and in plasma collection, and is a world leader in transfusion 
medicine. This company pays for plasma extractions for reasons of efficiency. They 
consider from a point of view of public health and justice that there must be a right of 
access to treatment that will cure as many patients as possible and ensure a reasonable 
cost for the system, providing the best quality of life and allowing the patient access to a 
continuous supply of blood as needed for healing. The time and effort that the person 
engages in the extraction justifies payment.  
 
The ethical foundation is utilitarian: an action is ethically better than another if 
it benefits a greater number of people. The aim is to reach all patients, to continue 
curing diseases, to save lives and to have sufficient surplus to allow research and to 
manufacture drugs. That is considered reasonable, especially because today there is no 
alternative to current treatments. 
 
One of the most compelling reasons for compensation is that if altruism is 
required for extraction, it should also be required of the doctor, the head of the center, 
the bag supplier and all those who collaborate in obtaining this tissue. On the contrary, 
this entire chain of people who are professionally involved in the extraction are paid for 
their time and commitment. The payment quantifies the time spent on one or another 
type of collection. It is thus considered ethical as it also remunerates the donor by 
showing gratitude and values their effort. Furthermore, if a private company generates 
                                                             
25 Ibid., p. 27 
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profit from a raw material, it is ethical that the primary "provider" also receives 
payment. 
 
Another argument refers to the concept of freedom: consider that those who sell 
are as free to do so as those who give away; the fact that there is a financial benefit 
through this medium does not annul the capacity of decision-making, and so there is no 
apparent possibility of coercion. Moreover, freedom is also the faculty to dispose of 
one’s body as one sees fit (principle of self-determination). 
 
Remuneration is not considered harmful to the dignity of people: this concept is 
quite extended and varies according to each culture and individual. However, what is 
harmful is that there is not enough blood to cure those who depend on it. The end 
justifies the means to achieve it; in this case, the purchase of blood from people who 
freely decide to sell it. 
 
Henry Grabowski and Richard Manding in their article Economics and ethics of 
plasma donation set out a list of benefits that are attained by remunerating for 
extractions. They are: consistency and frequency of donations, thanks to the financial 
incentive, that allows the control of donors; the increased volume of extractions, which 
increases performance in research and manufacturing tasks; or the diversity that is 
achieved, as more people are attracted, and that makes it easier to get, for example, 
particular types of antibodies that are not always present in all blood types.
26
 
 
The paid model is clearly viable as it supports global demand and, therefore solves a 
significant ethical problem: that thousands of patients can have access to adequate 
medical treatment. But questions arise on the criteria of social utility and facts: if it is 
ethical to pay, what should the price be? Who decides? And, on the other hand, is 
medication resulting from the extraction accessible to all on equal terms? This does not 
seem to be the case in the United States. Remember that it is advisable that what is 
ethical should be efficient, but not everything that is efficient is ethical per se. 
 
 
 
                                                             
26 Op. cit., Grabowski, H., Manding, R., p. 16 
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Criticisms of the paid model 
 
The main argument is upheld by the evidence that the paid model is efficient: 
“Debates on ethical issues around giving rewards for donations should be encouraged. 
But there should be little debate that the most relevant empirical evidence shows 
positive effects of offering economic rewards on donations.”27 
 
In this case, the end justifies the means. But advocates of altruism believe that there 
are limits that should not be crossed: what are the benefits that are defended by those 
supporting a paid model? Are both models equally ethical? 
 
One of the economic arguments for compensation is that "financial incentives leave the 
donor in a better financial position.”28 This argument fits perfectly with the concern 
that there is among advocates of altruism that some of the "donors" are there because 
they need the money, with all the ethical consequences that this entails. Can it be said 
that these people decide freely or does their vulnerability push them into it? In the paid 
model the possibility of coercion increases: 
 
“Donors sit upright on uncomfortable, hard chairs. Some have just come off night 
shift; others have no money for food. Staffs are concerned about how many units 
will test positive from blood-borne viruses. Potential donors worry about being 
accepted. A woman without an up-to-date residency certificate is turned away. A 
man insists he should be allowed to donate; he is broke and desperate for the 850 
roubles (£8.85) payment. It is clear that most donors come for the money: for some, 
it is a lifeline.”29 
 
Compensation may infringe upon human dignity, instrumentalizing the body, 
against the principle of social justice, coercing the most disadvantaged who do not 
possess private insurance. Moreover, it could also reduce the will for altruism of society 
and ruin the model in other areas such as in organ transplantation. The dogmatism of the 
facts can make us forget ethical limits.  
  
                                                             
27 Lacereta, N.,  Macis, M., Slonim, R.,  Economic Rewards to Motivate Blood Donations. Policy Forum, 
Public Health, 2013, p. 928 
28 Op. cit., VV.AA., p. 7 
29 Harvey J., "Blood money: is it wrong to pay donors?", The Guardian (January 25th, 2015) 
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One must be conscious of the main problem and what each model achieves. The 
thesis is not exclusion, but the complementarity of both models.  
 
 
Ethical evaluation of the two models 
 
Regarding the principle of beneficence, the altruistic model qualifies by 
promoting social and community values and thus educating in the moral obligation to 
act for the benefit of others. The model also respects this principle since it is self-
sufficient and guarantees that dependent patients always have and will not lack 
treatment. 
 
Regarding the principle of maleficence, by which no intervention should cause harm 
and should be proportionate, the altruistic model respects it. It is necessary to consider 
which the greater evil is: that patients should not have access, or that they should have it 
by “extorting” healthy persons? It is a model that respects dignity as it avoids exploiting 
and abusing the disadvantaged. On the contrary, the paid model does not care for the 
economically insecure, and that breaches this principle. Depending on which view one 
has of human dignity, this is also affected since remuneration exploits the individuals 
who, by being in need, trade in their own bodies.
30 
 
The principle of self-determination is guaranteed in the altruistic model as there is 
no form of gratification; donation becomes an end in itself, which ensures that the will 
of those who give is free and disinterested. This is also fulfilled in the paid model based 
on individual will and freedom to dispose of one's own body. The will to have an 
extraction drawn is free since it is known that material or financial interest is the driving 
force that may condition, but does not delegitimize or nullify it. It may be questioned 
however, by alleging that the donor has not been provided with all the information 
regarding the route the person’s blood takes once it has been sold. There is very little 
information on whether intermediary companies cover costs or make profits with the 
sale of medicines they manufacture. If one is not afforded this knowledge, the users are 
                                                             
30 Imagine the case of a donor who has a rare blood type; could it be sold at a higher price? The donor 
could set the price and negotiate. A very clear line should separate compensation for the inconvenience, 
from making money on it. 
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not equitably informed, and therefore, they are not provided with fair transparency, 
accessibility and proximity. 
 
Finally, regarding the principle of justice, the altruistic model does take it very much 
into account. By not paying for this resource, it causes blood to pass into the public 
domain and access to medication or transfusions to be more equitable within a public 
health system; it thus respects equitable distribution of scarce resources. It is a fact that 
in the United States the paid model coexists with the altruistic one, but it should be 
investigated whether the remuneration of extractions causes a decline in voluntary 
donations, although it is somewhat complex to ascertain categorically. Remuneration 
takes into account the physiological effort and time the donor devotes to it and that it is 
quantifiable; under this principle, providing financial compensation is therefore 
coherent. That this means an increase (moderate) in the final cost of blood products is 
reasonable for the system, given that it provides a better quality of life to those who 
most need it, ensuring domestic self-sufficiency. 
 
It can be concluded that the altruistic model turns out to be ethical in itself. This 
model is linked to the conception of a public and universal healthcare model. 
Unfortunately, at present, it is inefficient. The paid model justifies itself as it can cope 
with the current demand for blood. It is a model based on the casuistry of the facts. 
Efficiency, in consequence, converts it into an ethical model. However, by allowing 
certain coexistence with the altruistic model it reveals the widespread conception that 
the latter is considered desirable despite its inefficiency.  
 
Besides the four principles, there are other elements to consider when assessing the 
two blood collection models. It is important to think about what kind of healthcare 
model is desirable and whether it should be universal. It would be good if blood were 
kept as a public good accessible to all. Paying for what is needed is justifiable, but it 
cannot be the principle upon which to base the action, but rather just another argument. 
On the other hand, ethics seeks universal principles to legitimize actions. If altruism 
were to achieve self-sufficiency, the argument for compensation would collapse, and 
thus it cannot be the fundamental principle of this model. 
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It is necessary to ascertain what we are looking for when we say the best 
obtention model, and to assess what limits should not be crossed and if both models are 
equally ethical. What does better mean? What ethical and anthropological theory and 
what model of society lie behind it? Within the capitalist system, monetary 
remuneration is efficient, and perhaps also ethical: compensation is utilitarian. But that 
the model is efficient does not mean it is ethical. If payment is prohibited, it is for 
ethical reasons and not for simply gaining medical or healthcare efficiency. 
 
The altruistic model does not generate as many ethical doubts, even though since 
it does not achieve self-sufficiency (a fact that could be described as maleficent 
regarding the sick), it purchases what it is short of from the model it repudiates. 
 
The ethical evaluation of each model depends on where it frames the criteria 
from which the ethical and anthropological theory is observed. Therein lies the 
difficulty of considering certain arguments as decisive. The arguments for the paid 
model are based on the lesser evil which monetary reward implies in the face of the 
need for blood and they have a very different ethical basis from the altruistic model: it 
seems that remuneration is legitimate as long as the altruistic model is not self-
sufficient. These arguments are of a consequentialist nature: it is the end of the action 
which legitimizes it. But can an efficient action be placed at the same level as one that is 
legitimate and ethical? Would advocates for compensation accept altruism as the only 
model if it were shown that it can achieve self-sufficiency? No argument is brandished 
against altruism per se, but its inability to achieve self-sufficiency discredits it. 
 
The paid model is efficient but generates unease by including blood within the 
law of markets and commercialization and turns it into a tradable product. The altruistic 
model does not generate ethical doubts but of efficiency: this is an instrumental 
resource, sometimes necessary for the common good, but that by itself may not always 
be the ultimate goal if it goes against the ends it pursues. Efficiency should serve moral 
purposes, as are freedom, justice, solidarity and welfare - not supplant them. 
 
The arguments for the altruistic model are mainly of an deontological nature and 
focus on what it should be, and what should be done to take into account the common 
interest and not only whatever is the most immediate problem. It should be addressed 
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according to ethics and not just what is simply efficient, since what is correct and 
efficient do not always go hand in hand. Paying for something that comes from human 
beings, but is expected to yield positive  consequences, is in itself ethically reviewable 
in our anthropological tradition and consistent with the model of society we seem to 
want (just, solidarity, fostering human dignity and integrity...). Weighing up the greater 
or lesser evils implies clarity regarding what the evil is. 
 
All things considered, from an ethical point of view the altruistic model is more 
easily defensible than the paid model. But the worldwide lack of blood makes it difficult 
to maintain the value of altruism. All this forces us to foster a culture of donation. 
 
 
A public health and civic ethics issue 
 
Blood is a product for transferring between people and is used for healing various 
diseases. One wonders whether we consider blood a public or private good and 
consequently, whether it should be managed by the state. The debate takes on a 
biopolitical dimension. 
 
Converting blood into a product governed by the law of markets creates ethical 
problems of various kinds: 
 
Who sets the price? This may vary from country to country; it is not the same to pay 
twenty Euros for blood in Nigeria than in Spain. It is quite different to do so in a poor 
country than in a rich one, or in a country with an extensive public health network or 
elsewhere that lacks one. The social context may mean having to legislate very 
differently for the same thing. Pricing often depends on collective agreements and 
insurers, among others; but a drug is a global commodity, manufactured and sold at 
differentiated specific places and prices, in the same manner as other types of goods. 
The difference is that a drug cannot be equated to any commodity; these blood-
derivatives are vitally necessary products that respond to the right to health. 
 
One important issue is whether advocates for remuneration would accept the 
altruistic model if it were shown that it could be self-sufficient, or whether they would 
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continue defending compatibility; in the latter case, the argument for freedom would 
prevail for both the donor and the company. But if blood became a public good and the 
state determined prices, that would imply limitations for the pharmaceutical industry. 
 
There should be proportionality between what is paid for extraction and what is 
obtained from the sale of the drug. The objective is the end-user (cures and improves the 
quality of life for people in need) and should as far as possible shun profit, although 
bearing in mind that intermediaries should be compensated for the work they do. There 
must be a market, but sufficiently controlled and regulated. 
 
The issue directly affects WHO –scientific research and patents– and broad and 
comprehensive consideration is required to find a fair and equitable solution for all. It is 
extremely important to create spaces for global bioethical and biopolitical deliberation, 
beyond national institutions and traditional markets. We must reflect on a new theory of 
justice that covers the acquisition and management of limited resources. We are 
confronted with civic ethics and justice for public health, a global issue. 
 
 
Conclusions 
 
Principlism has its theoretical and practical difficulties. The principles that are used 
to make moral judgments are indeterminate, abstract and ambiguous; this fact gives rise 
to multiple interpretations and conceptions of the idea of benefit, prejudice, autonomy 
and justice. Therefore, the principles applied to determine the ethics of the two models 
have a close relationship with the ideological position from which they are valued: 
liberal individualism leads to a utilitarian position while social cooperativism takes an 
ethical stance. American bioethics generally arises from an individualistic anthropology 
and an individualized conception of humankind, and so its model for blood collection is 
more liberal as opposed to European bioethical interpretations. These work from a more 
cooperative anthropology and see the human being as cooperative, interdependent and 
prioritizes social ties. In Europe, there is usually a shared conception of good and a 
commitment to the public sphere where collective benefits are considered. In the 
American conception, the defense of individual liberties to attain fair distribution 
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prevails. Depending on what kind of society we want to build, one or the other will be 
better suited. 
 
Bioethical consideration should provide a solid basis for moral judgments. In this 
article, we are interested in the concept of justice as equitability and as a defense of 
human rights, with a philosophical basis in mutual recognition among peers. A model of 
a just society is one that assigns certain rights and duties to both citizens and their 
institutions. One should not forget that the model of society is related to the educational 
model, which should build solidarity citizenship for a cooperative society based on 
transparency where society can trust their institutions. Private enterprise must also 
prove transparent and work in coordination with the public sector. It is about finding the 
right balance between public authority and private power, creating a harmonious and 
supportive relationship between them and, ultimately, understanding health as a matter 
of minimum civic ethics. 
 
For this reason, the debate about decision making has to be part of the entire society 
and has to be democratic. Precisely because health is a global issue, comprehensive 
solutions must be sought through a universal criterion of justice which, by involving the 
public, private and global powers, will naturally lead to overcoming the inconsistencies 
of the two existing models of blood and plasma donation. From a deep and thorough 
study of the subject, a consensus would have to be reached among all the parties 
involved. 
 
This article has sought, to the extent of our possibilities; help shine some light on 
the various arguments in defense of either one or the other blood collection models. 
Since the technology and science are advancing very rapidly, another way to obtain 
blood and plasma might be found that will make extraction as we know it today 
obsolete, but so far this is not the case. 
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